SCLP Scancell Holdings plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. The company's product candidates include ImmunoBody, DNA active immunotherapies encode a protein in the form of a modified antibody; Moditope, a potent peptide active immunotherapy targeting tumour-specific neoantigens through the MHC-II presentation pathway; SCIB1 which is in phase I for adjuvant melanoma; SCIB1/iSCIB1+ that is in Phase III for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase III clinical trials for the treatment of solid tumors, including renal cell carcinoma, head, and neck; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company offers GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which promotes receptor clustering thereby improving immune signaling. Further, it provides pre-clinical products, such as SC129 and SC2811 for solid tumors; SC27; and GT 200 for ovarian cancer. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.…
Industry Peers
BiotechnologyKey Statistics
About Scancell Holdings (LON: SCLP)
›
Scancell Holdings (LON: SCLP) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 55 employees.
The shares were at 80.00 GBp on 19 November 2026, down 19.6% over 52 weeks. Its 52-week range is 78.00 GBp to 270.00 GBp: the price is 70.4% below the high and 2.6% above the low.
Its market capitalisation is 108.53M GBP.
Scancell Holdings reports return on equity of 92.2% and an operating margin of 0.0%.
Its debt exceeds its cash by 11.76M GBP. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 2 analysts cover the stock; their mean price target of 300.00 GBp is 275.0% above the current price.